Ed­i­tas’ ri­vals ap­peal a re­cent set­back on patent fight, map­ping a glob­al war for CRISPR su­prema­cy

Em­manuelle Char­p­en­tier

The gene edit­ing con­sor­tium that has sought to bot­tle up ri­val Ed­i­tas $ED­IT with claims of patent in­fringe­ment are mak­ing a fed­er­al case out of a re­cent set­back in the US.

In mid-Feb­ru­ary the US Patent Tri­al and Ap­peal Board ruled that there was no in­ter­fer­ence be­tween the two sides in the dis­pute, al­low­ing each to patent their work on CRISPR/Cas9 and car­ry on. But the Uni­ver­si­ty of Cal­i­for­nia, the Uni­ver­si­ty of Vi­en­na, and Dr. Em­manuelle Char­p­en­tier aren’t tak­ing no for an an­swer.

They have de­cid­ed to con­tin­ue the fight in fed­er­al court, ap­peal­ing the de­ci­sion to the U.S. Court of Ap­peals for the Fed­er­al Cir­cuit, tar­get­ing patents from The Broad In­sti­tute.

Jen­nifer Doud­na

The con­sor­tium in­cludes a group of biotech com­pa­nies found­ed on the IP es­tab­lished by Char­p­en­tier and her col­league Jen­nifer Doud­na: CRISPR Ther­a­peu­tics $CR­SP, In­tel­lia Ther­a­peu­tics $NT­LA, Cari­bou Bio­sciences and ERS Ge­nomics.

CRISPR/Cas9 re­search has ex­plod­ed in the last few years, spawn­ing a slate of biotech star­tups that are look­ing to use this new tech to ed­it dis­ease out of DNA. While still pre­clin­i­cal with years to go be­fore any prod­uct could con­ceiv­ably near the mar­ket, an­a­lysts and in­vestors have been whipped up by the rev­o­lu­tion­ary po­ten­tial of this tech­nol­o­gy, and the found­ing sci­en­tists have been at each oth­er’s throats over the IP.

Most patent fights in bio­phar­ma end with a sim­ple roy­al­ty agree­ment. But this time the fight is clear­ly per­son­al and the anger runs deep.

Feng Zhang

The group said to­day it is al­so wag­ing a glob­al patent bat­tle for CRISPR/Cas9 su­prema­cy over Ed­i­tas and its sci­en­tif­ic founder, Feng Zhang, who patent­ed the ri­val tech­nol­o­gy at The Broad.

They say they are “pur­su­ing ap­pli­ca­tions in the U.S. and oth­er ju­ris­dic­tions world­wide to ob­tain patents claim­ing the CRISPR/Cas9 tech­nol­o­gy and its use in non-cel­lu­lar and cel­lu­lar set­tings, in­clud­ing eu­kary­ot­ic cells. Cor­re­spond­ing patents have al­ready been grant­ed in the Unit­ed King­dom, and the Eu­ro­pean Patent Of­fice is al­so grant­i­ng a patent to UC, which will is­sue on May 10, 2017. UC’s ear­li­est patent ap­pli­ca­tion de­scrib­ing the CRISPR/Cas9 genome edit­ing tech­nol­o­gy and its use was filed on May 25, 2012, while the Broad’s ear­li­est patent ap­pli­ca­tion was filed more than six months lat­er, on De­cem­ber 12, 2012.”

How pre­pared is bio­phar­ma for the cy­ber dooms­day?

One of the largest cyberattacks in history happened on a Friday, Eric Perakslis distinctly remembers.

Perakslis, who was head of Takeda’s R&D Data Sciences Institute and visiting faculty at Harvard Medical School at the time, had spent that morning completing a review on cybersecurity for the British Medical Journal. Moments after he turned it in, he heard back from the editor: “Have you heard what’s going on right now?”

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Lina Gugucheva, NewAmsterdam Pharma CBO

Phar­ma group bets up to $1B-plus on the PhI­II res­ur­rec­tion of a once dead-and-buried LDL drug

Close to 5 years after then-Amgen R&D chief Sean Harper tamped the last spade of dirt on the last broadly focused CETP cholesterol drug — burying their $300 million upfront and the few remaining hopes for the class with it — the therapy has been fully resurrected. And today, the NewAmsterdam Pharma crew that did the Lazarus treatment on obicetrapib is taking another big step on the comeback trail with a €1 billion-plus regional licensing deal, complete with close to $150 million in upfront cash.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 144,400+ biopharma pros reading Endpoints daily — and it's free.

Scoop: Boehringer qui­et­ly shut­ters a PhII for one of its top drugs — now un­der re­view

Boehringer Ingelheim has quietly shut down a small Phase II study for one of its lead drugs.

The private pharma player confirmed to Endpoints News that it had shuttered a study testing spesolimab as a therapy for Crohn’s patients suffering from bowel obstructions.

A spokesperson for the company tells Endpoints:

Taking into consideration the current therapeutic landscape and ongoing clinical development programs, Boehringer Ingelheim decided to discontinue our program in Crohn’s disease. It is important to note that this decision is not based on any safety findings in the clinical trials.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Pearl Huang, Dunad Therapeutics CEO (Ken Richardson, PR Newswire)

Long­time biotech leader Pearl Huang takes the reins as CEO of No­var­tis-backed up­start

It has only been a few months since Pearl Huang exited the top seat at Cygnal Therapeutics, but now she’s back at the helm of another biotech.

After taking a few months off — passing an exam in that time to get her captain’s license from the US Coast Guard — she’s been named CEO of Dunad Therapeutics, a biotech focused on developing a small molecule covalent therapies that was founded in 2020. Huang told Endpoints News that two factors attracted her to going back to the c-suite: the company’s technology and its co-founders.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 144,400+ biopharma pros reading Endpoints daily — and it's free.

Matt Gline, Roivant CEO (John Sciulli/Getty Images for GLG)

Roivant chops sick­le cell gene ther­a­py, der­ma­tol­ogy drugs to fo­cus on 'high­er val­ue pro­ject­s'

Roivant is sweeping a suite of drugs, including a gene therapy for sickle cell disease already in the clinic, out of its pipeline.

Six programs from four of its “vants” are being wound down as part of “a company-wide cost optimization and pipeline reprioritization initiative to reduce our expected operating expenses and prioritize our capital resources.”

When reached by Endpoints News, a spokesperson said, “We don’t anticipate a material reduction in headcount but we will likely reassign some folks to higher value projects as part of winding down specific programs.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 144,400+ biopharma pros reading Endpoints daily — and it's free.

Laurence Reid, Decibel CEO

Still in pre­clin­i­cal test­ing for ear gene ther­a­pies, Deci­bel touts small snap­shot of chemo-in­duced hear­ing loss drug

Though Decibel Therapeutics has largely pivoted toward gene therapies for the inner ear, its lead clinical candidate simply aims to protect cancer patients from chemotherapy-induced hearing loss. On Tuesday, the biotech presented its first efficacy data for the program, and execs like what they see.

Decibel reported interim results from a Phase Ib study showing the experimental drug, dubbed DB-020, largely protected a small group of patients from losing their hearing. Researchers used a particularly unique study design, administering the compound in one of each patients’ ears before they received cisplatin chemotherapy and placebo in the other.

Alex­ion puts €65M for­ward to strength­en its po­si­tion on the Emer­ald Isle

Ireland has been on a roll in 2022, with several large pharma companies announcing multimillion-euro projects. Now AstraZeneca’s rare disease outfit Alexion is looking to get in on the action.

Alexion on Friday announced a €65 million ($68.8 million) investment in new and enhanced capabilities across two sites in the country, including at College Park in the Dublin suburb of Blanchardstown and the Monksland Industrial Park in the central Irish town of Athlone, according to the Industrial Development Agency of Ireland.

Fed­er­al judge de­nies Bris­tol My­er­s' at­tempt to avoid Cel­gene share­hold­er law­suit

Some Celgene shareholders aren’t happy with how Bristol Myers Squibb’s takeover went down.

On Friday, a New York federal judge ruled that they have a case against the pharma giant, denying a request to dismiss allegations that it purposely slow-rolled Breyanzi’s approval to avoid paying out $6.4 billion in contingent value rights (CVR).

When Bristol Myers put down $74 billion to scoop up Celgene back in 2019, liso-cel — the CAR-T lymphoma treatment now marketed as Breyanzi — was supposedly one of the centerpieces of the deal. After going back and forth on negotiations for about six months, BMS put $6.4 billion into a CVR agreement that required an FDA approval for Zeposia, Breyanzi and Abecma, each by an established date.

Ben Zimmer, Priovant CEO

Roivant un­veils lat­est spin­out as Pfiz­er en­trusts JAK1/TYK2 to Pri­o­vant

In November, Pfizer disclosed it’s spun out the Phase II dual JAK1/TYK2 inhibitor to a startup formed in collaboration with an unnamed, experienced partner.

We now know who the partner is. And as Pfizer and Roivant officially take the wraps off Priovant Therapeutics, the companies reveal that they have started two registrational trials of the drug, brepocitinib, as part of a broader plan to develop a big, first-in-class franchise spanning multiple orphan and specialty autoimmune diseases.